Copaiba-based Mouthwash in Oral Mucositis Prevention/Treatment During Radiotherapy
Oral Mucositis
Enrolment: 0 · Results not recorded
Loading the evidence…
Nutraceutical · beta-Caryophyllene (major sesquiterpene of copaiba oil-resin; reported CB2 receptor agonist); no curated ChEMBL mechanism record
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Oral Mucositis
Enrolment: 0 · Results not recorded
Head and Neck Neoplasms · Mucositis Oral · Radiotherapy; Complications
Enrolment: 20 · Results not recorded
Dentin Sensitivity
Enrolment: 75 · Results not recorded
Tooth Bleaching Pain
Enrolment: 75 · Results not recorded
Chronic Low-back Pain
Enrolment: 300 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Standardised transfixing (through-and-through) traumatic injury of the anterior tongue, one perforation in each lobe, damaging epithelial, connective and muscle tissue
Copaiba oil-resin reduced the chronic inflammatory infiltrate score (1.2 +/- 0.20 versus 2.0 +/- 0.0 in controls) and significantly lowered CD68-positive macrophage counts (p = 0.0432), with effects comparable to dexamethasone; the reduction in oedema was not statistically significant.
Extraction: extract · Supplied extraction confidence: 0.92. Machine-extracted fields require source verification.